The prognostic role of tumour regression grade after neoadjuvant chemotherapy in patients with resectable gastro-oesophageal adenocarcinoma

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter A. Tin
Citation Annals of Oncology (2016) 27 (2): 102-117. 10.1093/annonc/mdw200
Authors A. Tin, E. Smith, N. Wadd, D. Wilson
  • James Cook University Hospital, Middlesbrough, United Kingdom, /

Abstract

Perioperative chemotherapy with epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/X) has been widely regarded as the standard of care for patients with resectable gastro-oesophageal adenocarcinoma. There is limited evidence to suggest that pathological response as indicated by tumour regression grade (TRG) has prognostic value in gastro-oesophageal adenocarcinoma. The aims of this study were to assess the effectiveness of perioperative ECX and to assess the prognostic value of TRG.